Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116219 | 1.00 | CHRM2 (0.67) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL10098300 | 0.84 | CHRM2 (0.70) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL10098329 | 0.84 | CHRM2 (0.73) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL19982655 | 0.83 | CHRM2 (0.74) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL10098315 | 0.83 | CHRM2 (0.74) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL10098303 | 0.81 | CHRM2 (0.69) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL1158251 | 0.81 | CHRM2 (0.62) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL4659057 | 0.81 | CHRM2 (0.62) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| SCHEMBL16166473 | 0.80 | CHRM2 (0.70) | CHRM2CHRM1ALOX15ADRB2ADRA2A | |
| Fesoterodine SCHEMBL15148766 | 0.80 | CHRM2 (1.00) | CHRM2CHRM1ALOX15ADRB2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| EP-2855421-A2 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | Crystal Pharma S.A.U (ES) | 2015-04-08 | — | — | EP | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| EP-2281801-B1 | Process for obtaining 3,3-diphenylpropylamines | CRYSTAL PHARMA SAU (ES) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013113946-A2 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA, S.A.U. (ES) | 2013-08-08 | — | — | WO | disclosed |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | CURIA SPAIN, S.A.U. (ES) | 2012-08-30 | — | — | US | disclosed |
| EP-2281801-A1 | Process for obtaining 3,3-diphenylpropylamines | Ragactives, S.L.U. (ES) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | ADRB3, CHRM3, CYP4F3 | CHRM2 8/4885CHRM1 12/4885ALOX15 4707/4885 |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | ADH1C, NISCH, ADH1A | CHRM2 10/4885CHRM1 11/4885ALOX15 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.